KRAS and non-small cell lung carcinoma: Following are the prevalence of actionable mutations among NSCLC patients: ALK: 4.1%-21.4%, BRAF: 1.5%-3.5%, EGFR: 11.9%-51.8%, HER2: 0%-1.5%, KRAS: 4.5%-6.4%, NTRK: 0%-.7%, and ROS-1: 3.5%-4.1%.15